Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

X4 Pharmaceuticals, Inc. Common Stock (XFOR)

Biological Products, (no Disgnostic Substances)

https://www.x4pharma.com

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream.

61 NORTH BEACON STREET, 4TH FLOOR
BOSTON, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/16/2017

Market Cap

115,843,750

Shares Outstanding

167,290,000

Weighted SO

167,291,209

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

TERN --.--%

DAWN --.--%

PDSB --.--%

INZY --.--%

ABOS --.--%

MREO --.--%

EFTR --.--%

ELEV --.--%

HEPA --.--%

Beta

0.3470

Last Div

0.0000

Range

0.531-1.6

Chg

0.0552

Avg Vol

2063300

Mkt Cap

115843750

Exch

NASDAQ

Country

US

Phone

857 529 8300

DCF Diff

0.4582

DCF

0.2316

Div Yield

0.0000

P/S

205.7615

EV Multiple

-0.3848

P/FV

1.4590

Div Yield %

0.0000

P/E

7.8155

PEG

0.1271

Payout

0.0000

Current Ratio

6.0693

Quick Ratio

6.0406

Cash Ratio

5.0937

DSO

553.6590

DIO

278.7822

Op Cycle

832.4411

DPO

2679.1268

CCC

-1846.6857

Gross Margin

-0.9325

Op Margin

-219.5364

Pretax Margin

31.4885

Net Margin

31.3179

Eff Tax Rate

0.0054

ROA

0.0837

ROE

0.3293

ROCE

-0.6802

NI/EBT

0.9946

EBT/EBIT

-0.1434

EBIT/Rev

-219.5364

Debt Ratio

0.3618

D/E

0.8068

LT Debt/Cap

0.4427

Total Debt/Cap

0.4465

Int Coverage

-38.4086

CF/Debt

-1.4757

Equity Multi

2.2298

Rec Turnover

0.6593

Pay Turnover

0.1362

Inv Turnover

1.3093

FA Turnover

0.0991

Asset Turnover

0.0027

OCF/Share

-0.5610

FCF/Share

-0.5622

Cash/Share

0.8419

OCF/Sales

-199.7318

FCF/OCF

1.0021

CF Coverage

-1.4757

ST Coverage

-95.9462

CapEx Coverage

-476.4788

Div&CapEx Cov

-476.4788

P/BV

1.4590

P/B

1.4590

P/S

205.7615

P/E

7.8155

P/FCF

-1.0280

P/OCF

-1.2255

P/CF

-1.2255

PEG

0.1271

P/S

205.7615

EV Multiple

-0.3848

P/FV

1.4590

DPS

0.0000

Latest Headlines (EST)

MarketWatch Jan 06, 05:58 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks GlobeNewswire Inc. Dec 09, 12:00 X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023 GlobeNewswire Inc. Dec 09, 12:00 X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023 GlobeNewswire Inc. Dec 09, 12:00 X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023 GlobeNewswire Inc. Dec 09, 12:00 X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023 GlobeNewswire Inc. Dec 09, 12:00 X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

Revenue Product Segmentation